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Introduction
The discovery of human T-1ymphotropic virus type III (HTLV-III)/lymphadeno-
pathy-associated virus (LAV) has intensified two lines of research which might
potentially lead to control of the acquired immunodeficiency syndrome (AIDS) and
a set of related diseases; 1) the development of a vaccine to protect persons who
are not already infected with HTLV-III/LAV or are in a very early stage of infec-
tion, and 2) the development of agents active against HTLV-III/LAV which may have
therapeutic effect in persons who are already infected*
In this paper, we would like to describe several in vitro systems that we
have developed to assess the activity of agents against HTLV-III/LAV; to discuss
the in_ vitro antiviral activity of 2!,3f-dideoxynucleoside analogues; and to
report results of phase I clinical trial of one of the 2?,3'-dideoxynucleoside
derivatives, 3'-azido-3'-deoxythyraidine (also called AZT or BW A509U). The
structures of dideoxynucleoside analogues discussed in this paper are provided in
Figure 1.
Development of Systems for Assessing Activity of Agents against HTLV-III/LAV
In the spring of 1984, after a new pathogenic retrovirus (HTLV-III/LAV) was
proven to be the causative agent of AIDS and quantities of purified virus became
available (Barre-Sinoussi et al, 1983; Popovic et al., 1984; Broder & Gallo,
1984; Wong-Staal & Gallo, 1985), we started to develop an anti-HTLV-III/LAV drug
screening system in the Clinical Oncology Program of the National Cancer Insti-
tute.
We have now utilized a variety of approaches in the screening of drugs for
potential usefulness in HTLV-III/LAV-related diseases (Table 1). In the initial
step of screening we perform the HTLV-III/LAV cytopathic effect inhibition assay
in which an immortalized T-cell line (ATH8) (vide infra) that is profoundly
sensitive to the cytopathic effect of HTLV-III/LAV is used as target T-cells
(Mitsuya et al., 1985a; Mitsuya & Broder, 1986). Clone ATH8 was generated by
cloning a normal tetanus-toxoid specific T-cell line in the presence of human
T-cell lymphotropic type I (HTLV-I) as previously described (Mitsuya et al.,
1984a) and was selected for this study on the basis of its rapid growth [in the
presence of Interleukin 2 (IL-2)] and readily apparent sensitivity to the cyto-
pathic effect of HTLV-III/LAV. Clone ATH8 bears several distinct copies of
HTLV-I in its genome when assessed by Southern blot hybridization using a radio-
labelled HTLV-I probe but nevertheless does not produce detectable amounts of
HTLV-I gag proteins (Mitsuya, Reitz, and Broder; unpublished). It should be noted
that several other HTLV-I-infected cell lines (e.g. MT2 and MT4) have been re-
ported by Harada and Yamamoto to be sensitive to the cytopathic effect and infec-
tivity of HTLV-III/LAV (Harada et al., 1985).
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FIGURE 1. Structures of dideoxynucleosides discussed in this paper. The primed numbers
(very left) refer to positions in the sugar moiety of nucleosides.
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TABLE I. In Vitro Systems for Assessing Activity
of Agents against HTLV-III/LAV.
1 . Protection of antigen-specific helper/inducer T-cells against
the cytopathic effect of HTLV-tllg, using normal and
immortalized target cells.
2. Protection of target T-cells against the cytopathic effect
of HTLV-III/RF-II {a variant of HTLV-lli isolated from a
Haitian patient), as an additional control for HTLV-lll-isolate
variability.
3. Inhibition of viral p24 expression in H9 cells, following
exposure to HTLV-lllg.
4. Detection of HTLV-lll DNA (using Southern blot hybridization)
and RNA (using Northern blot hybridization) in target T-cells
exposed to the virus in the presence and absence of the drug.
5. Effects on immune functions of normal T-cetls in vitro.
completely killed by the virus by day 7 of
When ATH8 cells are cultured
in a test tube, these cells form
a pellet at the bottom of the
tube and the pellet size reflects
the number of viable target T-
cells. Under these conditions
>
the cytopathic effect is amenable
to direct visual inspection. When
exposed to HTLV-III/LAV, in the
absence of protective drugs, the
virus exerts a profound cytopath-
ic effect on the target T-cells
byday 4 in culture; by day 10,
>98% of cells are killed by the
virus and pellet' of ATH8 cells
is essentially completely dest-
royed. For example, as shown in
Figure 2, ATH8 cells are almost
culture following exposure to the
virus (upper right). However, upon the addition of 2 uM 2r,3f-dideoxycytidine
(ddCyd) ATH8 cells are completely protected against the HTLV-III/LAV cytopathic
effect and ATH8 cells are able to survive and grow (lower right) comparably to
the virus-unexposed and drug-exposed control cells (upper left). It should be
noted that the pellet size of ATH8 cells exposed only to ddCyd (lower left) is
comparable to that of the virus-unexposed and drug-unexposed cells (upper left).
The HTLV-III/LAV cytopathic effect inhibition assay thus permits the simultaneous
assessment of potential anti-viral activity and toxicity of selective compounds.
This assay is readily adaptable for mass screening (e.g. in microtiter plates).
When nucleosides are tested in this system, various concentrations of the com-
pounds are added to the culture following exposure to the virus. When possible
neutralizing antibodies or certain compounds which slowly penetrate into cells,
target cells are exposed to such agents prior to exposure to the virus and then
continuously throughout the assay.
Anti-HTLV-III/LAV Activities of 2T ,3'-Dideoxynucleosides
To date, we have scre'ened more than 250 different compounds including some
120 nucleoside derivatives for anti-HTLV-III/LAV activity. We have found that
essentially every purine and pyrimidine nucleoside with a 2',3f-dideoxy-ribose
moiety can block the infectivity and cytopathic effect of HTLV-III/LAV in vitro
(Mitsuya & Broder, 1986). Figure 3 shows the potent protecitve effect of 2I,3I-
dideoxynulceosides on the survival and growth of ATH8 cells when exposed to HTLV-
III/LAV. We found that concentrations of >10 uM 2T,3T-dideoxyadenosine (ddAdo),
2',3f-dideoxyguanosine (ddGuo), 2',3'-dideoxyinosine (ddlno), as well as con-
centrations of >0.5 uM 21,3'-dideoxycytidine (ddCyd) completely protected ATH8
cells and enabled them to survive and grow. These compounds exhibited a strong
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FIGURE 2. Cytopathic effect of HTLV-III/LAV on clone
NO DRUG






ATH8 and protection by 2',3'-dideoxycytidine. ATH8
cells (2xl05) were exposed to HTLV-IIIg (3,000
virus particles per cell) and cultured in test
tubes in the presence or absence of 2',3'-dideoxy-
dideoxynucleosides. By day 7 of culture, ATH8
cells were almost completely killed by the virus.
The cytopathic effect can be seen as a small dis-
rupted pellet which contains debris of cells (upper
right). In the presence of 2',3'-dideoxycytidine,
ATH8 cells were completely protected and continued
to grow, which can be seen as a large cell pellet
(lower right) comparable to that of HTLV-IIIg-unex-
posed, drug-unexposed ATH8 population (upper left).
ATH8 cells exposed to only drug (lower left) formed
a large pellet comparable to that of the control
virus-unexposed, drug-unexposed cells (upper left).
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anti-viral effect at doses that were lower by a factor of 10 to 20 than those
that inhibited growth of the target cells when no virus was present. Under our
experimental conditions, 21 ,3'-dideoxythymidine (ddThd) required relatively high
concentrations to exert a protective effect, and unlike the other comparable
dideoxynucleosides tested, its capacity to nullify the aytopathic effect of the
virus was lost on day 10 of culture (data not shown).
The protective effects of 2f,3'-dideoxynucleosides were confirmed in normal
cloned helper/inducer T-cells (TM3) cocultured with irradiated HTLV-II^-pro-
ducing H9 cells (H9/HTLV-IIIB) (H9/HTLV-IIIB cells serve as a source of infectious
virions, and theoretically both cell-free and cell-associated virus transmission
can occur). Moreover, the anti-HTLV-III/LAV activity of dideoxynucleosides was
confirmed by their inhibitory effect on the expression of HTLV-III/LAV p24 gag
protein in H9 cells.
In order to determine whether the 2f,3'-dideoxyribose moiety was necessary
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capacity of five closely related adenosine congeners
[2*,3'-dideoxyadenosine, 2f-deoxyadenosine, 3f-de-
oxyadenosine (also called cordycepin), adenine ara-
binoside (ara-A), and 2',3f,5'-trideoxyadenosine]
to block the cytopathic effect of HTLV-III/LAV
(Mitsuya & Broder, 1986). Results indicate that at
least among these closely related adenosine conge-
ners tested, only adenosine with a 2',3'-dideoxy-
ribose moiety has an anti-HTLV-III/LAV activity.
It is worth noting that 2r,3'-dideoxynucleo-
sides and related compounds such as 3f-azido-3f-de-
oxythymidine are not new chemicals and pioneering
studies on several of these compounds were initi-
ated in the 1960's and 1970's, before human retro-
viruses were proved to exist (Robins & Robins, 1964;
Horwitz et al., 1964; HcGovern et al, 1966; Toji &
Cohen, 1969; Lin & Prusoff, 1978).
FIGURE 3. Inhibition of cytopathic effect of HTLV-III/LAV by 2',3'-
dideoxynucleosides against ATH8 cells. ATH8 cells (2xl05) were
pre-exposed to polybrene, exposed to HTLV-IIIB (2,000 virus
particles per cell) and cultured in test tubes (solid columns)
in the presence or absence of various concentrations of 2'>3I-
dideoxyadenosine, -guanosine, -inosine, -cytidine, or -thymidine.
Control cells (open columns) were similarly treated, but were not
exposed to the virus. On day 5, total viable cells were counted.
Reproduced by permission of the Proceedings Office of the Nation-
al Academy of Sciences, USA (Mitsuya & Broder, 1986).
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FIGURE 4. Lack of HTLV-III/LAV mRNA expression
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b ut protected by 2',3'-dideoxyadenosine or
2',3'-dideoxycytidine. 2xl07 ATH8 cells were
treated with polybrene, exposed to HTLV-IIIg
(1,000 virus particles per cell), resuspend-
ed, and cultured in the presence or absence
of 50 uM 2',3'-dideoxyadenosine or 2 uM 21,
3'-dideoxycytidine in culture flasks. On days
1, 2, 3, and 8 following exposure to the
virus, total RNA was extracted and subjected
to Northern blot hybridization using radio-
labelled HTLV-llI/LAV antisense RNA. The 9.3
kb segment represnts HTLV-I1I/LAV genomic RNA;
the 4.3 kb band env RNA; and the 2 kb tat-III
and 3'-orf RNA species. Control denotes total
RNA from ATH8 cells which were not exposed to
the virus.
Inhibition of HTLV-III/LAV DNA Synthesis and RNA Expression in T-cells Exposed to
the Virus.
In cells infected with HTLV-III/LAV, the virus can be detected as uninte-
grated and integrated viral DNA as well as viral mRNA (Hahn et al., 1984).
Southern and Northern blot hybridization techniques are potentially useful in
determination of the relative amounts of viral DNA and RNA of the virus-harboring
cells and tissues and have enabled us to detect HTLV-III/LAV even when the virus
is residing in the latent form.
We have asked if viral DNA and mRNA can be detected in susceptible T-cells
(ATH8) when exposed to the virus but protected by putative drugs. In a typical
experiment, ATH8 cells are exposed to HTLV-III/LAV and cultured in the presence
or absence of selective drugs. High molecular DNA is extracted at various times
and assayed for its content of viral DNA using a radiolabelled HTLV-III/LAV
probe. In the absence of protective agents under our culture conditions, viral
DNA is first detected by day 2, and a substantial amount of viral DNA is detected
on the following day. In contrast, in DNA from ATH8 cells which have been comp-
letely protected by certain effective drugs, neither unintegrated nor integrated
DNA is detected. We also ask whether viral mRNA is expressed in target T-cells
exposed to the virus and cultured with or without protective agents. Figure 4
shows that ddAdo and ddCyd completely inhibited the HTLV-III/LAV mRNA expression
in ATH8 cells exposed to the virus. In this experiment, ATH8 cells were exposed
to HTLV-IIIs (1,000 virions per cell), and RNA was extracted from ATH8 cells on
days 1, 2, 3, and 8 of culture. Extracted RNA was then assayed for the content
of viral mRNA by Northern blot hybridization using a radiolabelled HTLV-III/LAV
antisense RNA probe. In the absence of dideoxynucleosides viral mRNAwas detect-
able on day 2 and was present at a greater level on day 3. In contrast, when
cultured in the presence of 50 uM ddAdo or 2 uM ddCyd, viral RNA could not be
detected throughout the study. (Mitsuya, Jarrett, Matsukura, and Broder; unpub-
lished).
This assay system allows us to assess the capacity of drugs to inhibit HTLV-
III/LAV DNA synthesis and mRNA expression in T-cells exposed to the virus, and
also perhaps allows us to/assess the mechanism of the antiviral effects. Our
working conclusion is that the dideoxynucleosides can inhibit HTLV-III/LAV at the
point of reverse transcription (vide infra).
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Mechanism(s) of Anti-Retroviral Activity of 2' ,3'-Dideoxynucleosides
2',3'-Dideoxynucleosides are nucleoside analogues in which both the 21- and
3'-hydroxy (OH-) groups are replaced with a hydrogen. When the dideoxynucleosides
are converted to a triphophate form, it is not possible to form normal 5f->3!
phosphodiester linkages which are necessary for DNA elongation in the replication
of virus from an RNA form to a DNA form. Indeed, we have shown that ddCyd is
converted to a triphosphate by cellular enzymes (Cooney et al., 1986), and the
triphosphate product is utilized by HTLV-III/LAV DNA polymerase (or reverse tran-
scriptase; RT) and inhibits DNA synthesis mediated by purified HTLV-III/LAV RT.
Certain dideoxynucleosides as a triphosphate form can thus act as DNA chain
terminators in viral DNA synthesis although this need not be the only mechanism
for anti-retroviral activity. It has been shown that the 5*-triphosphate pro-
ducts of ddAdo, ddGuo, ddCyd, and ddThd can rather easily inhibit mammalian DNA
polymerases beta, gamma, as well as RT of animal retroviruses, but not mammalian
DNA polymerase alpha (Waqar et al., 1984); and a similar observation has been
made by us with HTLV-III/LAV (Mitsuya, Spigelman, Veronese, McCaffrey, Sarngad-
haran, and Broder; unpublished), DNA polymerase alpha is assumed to be the key
DNA synthetic enzyme for DNA replication during cell growth, and it also has a
role in DNA repair (Waqar et al., 1984; Miller & Chinault, 1982; Krokan et al.,
1979). These four dideoxynuclesides have rather negligible short-term effects on
the growth of cultured mammalian cells (Waqar et al., 1984). Indeed, at concen-
trations that suppressed the replication of the virus, virtually all dideoxy-
nucleosides we tested failed to affect the growth and function of normal T-cells
except at very high doses (Mitsuya & Broder, 1986). DdAdo and ddCyd have been
selected for testing in humans with HTLV-III/LAV infection, and ddCyd is present-
ly undergoing animal toxiclty testing.
We believe 2* ,3f-dideoxynucleosides could potentially have an effect against
any retrovirus. For example, we have recently found that two dideoxynucleosides,
ddCyd and 3'-azido-3'-deoxythymidine (an azido derivative of ddThd), block the
infectivity of HTLV-I against normal helper/inducer T-cells (Matsushita, Mitsuya,
Reitz, and Broder; unpublished). We have also observed that 2! ,3f-dideoxynucleo-
sides can block the replication of certain animal retroviruses (Dahlberg, Mitsuya,
Broder, and Aaronson; unpublished). These properties, taken together, suggest
that at least some dideoxynucleosides are attractive candidates for further
development for treatment of human and veterinary retrovirus-related diseases.
In Vitro Administration of 3f-Azido-3f-deoxythymidine (AZT or BW A509U)
As noted above, we have found that some compounds which are chain termi-
nators for DNA synthesis can act as potent inhibitors of retroviral replication.
One such compound, 3T-azido-3'-deoxythymidine (also called AZT or BW A509U), has
recently been studied in a Phase 1 trial (Yarchoan et al. 1986). AZT is a ddThd
analogue in which the 3f-hydroxy group is replaced by an azido group (see Figure
1). At concentrations of 1 -3 uM, this drug inhibits the _in vitro infectivity
and cytopathic effect of HTLV-III/LAV in helper/inducer T-cells (Figure 5)
(Mitsuya et al., 1985a). Based in part on these in vitro data, a trial of AZT in
patients with AIDS and AIDS-related complex (ARC) was initiated at the National
Cancer Institute and Duke University Medical Center in collaboration with Well-
come Research Laboratories. In a 6-week clinical trial 4 dose regimens of AZT
were examined in 19 patients. The four dose regimens were A) 1 mg/kg intravenous
infusion (IV), then 2 mg/kg peroral administration (PO) every 8 hr; B) 2.5 mg/kg
IV, then 5 mg/kg PO every8 hr; C) 2.5 mg/kg IV, then 5 mg/kg PO every 4 hr; and
D) 5 mg/kg IV, then 10 mg/kg PO every 4 hr. Pharmacokinetic studies showed that
peak levels of 1.5 to 2 uM were attained following a one hour infusion of 1 mg/kg
or oral administration of 2 mg/kg and that the drug has a half-life of appro-
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FIGURE 5. Inhibition of cytopathic effect of HTLV-III/LAV by B'-azido-S'-deoxythymidine
against ATH8 cells. ATH8 cells (2xl05) were pre-exposed to polybrene, exposed to
HTLV-IIIg (2,000 virus particles/cell), and cultured in culture tubes (solid columns)
in the presence or absence of various concentrations of AZT. Control cells (open
columns) were similarly treated, but were not exposed to the virus. On day 5, total
viable cells were counted.
levels; for example, 5 mg/kg given intravenously over one hour yielded a peak
plasma level of 6 to 10 uM and a level of 0.6 uM4 hours after the start of the
infusion. In addition, sampling of the cerebral spinal fluid (CSF) showed pene-
tration of AZT. The drug was in general well tolerated during short term ad-
ministration; side effects were : 1) 5 - 10% hematocrit drops in several pa-
tients, 2) headaches in approximately half the patients, 3) tremors, confusion,
and neutropenia in one patient who was simultaneously receiving trimethoprim-
sulfamethoxazole, and 4) decrease in the total white blood count in half of the
patients on the highest two doses.
While the primary purpose of this study was to determine the safety and
feasibility of administrating AZT to patients with AIDS and ARC over 6 weeks, the
re'sults in addition indicated that immunological and/or clinical responses were
observed in some of the patients during this short-term administration. In par-
ticular, 15 of 19 patients had increases in numbers of their circulating helper/
inducer T-lymphocytes, 6 previously anergic patients gave positive skin test
during treatment, and the 1 patient in whom it was tested showed restoration
of a virus-specific cytotoxic T-cell response. Furthermore, 2 patients showed a
clearing of chronic fungal nailbed infections, 13 patients had weight gains of 2
kg or greater, and 6 patients had other clinical improvement. While it is likey
that these changes were the result of taking AZT, it is hard in such a small un-
controlled study to separate out such contributing factors as spontaneous im-
provement or a placebo effect.
Although our findings suggest partial immunological reconstitution in cer-
tain patients given AZT, it must be stressed that the increases in numbers of
helper/inducer T cells were often small and were most substantial during the
first 2 weeks of intravenous therapy; we cannot be sure that starting with an
oral course of therapy will yield similar results. Also, the decreases in helper/
inducer T cells or total white blood cells in some patients on the highest dose
tested suggest that this dose may be lymphotoxic. Recent observations suggest
that the accumulation of phophorylated AZT within cells causes a substantial
depression of thymidine triphophate (Balzarini and Broder, unpublished), and this
may contribute to the toxicity at high doses.
These initial results with AZT thus suggest that it can, at least for a 6
week period, induce immunologic improvemnt in patients with HTLV-III/LAV disease,
and that in some patients, it can yield other clinical benefits. A randomized
double-blind placebo controlled study of orally administered AZT is presently
being organized by Burroughs Wellcome Co. in several medical centers thoughout
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the United States to further evaluate this drug, specifically to determine
whether it can be tolerated for 6 months, whether it can yield immunologic bene-
fits over this time period, and whether it can reduce the morbidity and mortality
of patiens with AIDS. Such controlled trials will offer the best way of re-
solving the role of AZT in the therapy of patients with AIDS.
Conclusion
In the last two years, more than a dozen drugs have been identified to have
anti-HTLV-III/LAV activity (see Yarchoan et al., 1985 for review; Mitsuya et al.f
1984b; McCormick et al., 1984; Rosenbaum et al., 1985; Mitsuya et al., 1985b;
Broder et al., 1985; Sandstrom et al., 1985; Ho et al., 1985). While there is
clearly a long way to go before an effective therapy is developed for HTLV-III/
LAVdiseases, we hope we have gotten off to a good start. At least several
efficient screening systems for agents active against HTLV-III/LAV have been re-
ported and several drugs identified in these systems have been tested in patients
with HTLV-III/LAV infection. Also, we are gaining experience in the monitoring
of patients to identify clinical changes which may occur as a result of anti-
viral therapy in HTLV-III/LAV diseases. We believe that as we learn more about
HTLV-III/LAV, we can more rationally develop therapeutic strategies which might
have considerable value in attaking this disease.
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